search
Back to results

Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty

Primary Purpose

Coxarthrosis, Arthroplasties Hip Replacement, Perioperative Blood Loss

Status
Completed
Phase
Phase 3
Locations
Germany
Study Type
Interventional
Intervention
Etoricoxib
Diclofenac
Sponsored by
University of Regensburg
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coxarthrosis

Eligibility Criteria

55 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Indication for THA because of primary and secondary osteoarthritis of the hip.
  • male or female patients of the age of 55 - 85 years
  • informed consent afer having been informed in detail about the clinical trial by the investigator
  • negative pregnancy test (<= 2 days before inclusion) for women with child bearing potential (pre menopausal, <2 years menopausal, not surgically sterile), use of high security contraception methods as oral contraception agents or preservatives. The use of high security conception methods is also to obligatory for male patients

Exclusion Criteria:

  • Known hypersensitivity to one of the two investigational medical products or substaces of similar chemical structure or to any of the excipients
  • Patients who have experienced bronchospasm, asthma, acute rhinitis, urticaria, or allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors
  • unexplained dysfunction of haematopoiesis
  • treatment with NSAIDs or coxiben in the past 5 days before start of study
  • Active peptic ulceration or active gastro-intestinal (GI) bleeding
  • Pregnancy and lactation
  • Congestive heart failure (NYHA II-IV)
  • Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease
  • clinically relevant disease of the cardiovascular system, severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10), severe renal dysfunction (estimated renal creatinine clearance <30 ml/min, clinical relevant disease of the nervous system, the endocrinium or another severe systematic disease
  • Systemic lupus erythematodes or mixed connective tissue disease
  • Inflammatory bowel disease
  • alcohol or drug abuse during the last past 3 months
  • Patients with hypertension BP persistently > 140/90mmHG) and has not been adequately controlled
  • life expectancy <6 months
  • state of mind which does not enable the patient to understand the nature of the study, its importance and possible consequences
  • evidence that the respective person will not cooperate with the study protocoll
  • participation of the patient in another clinical trial during the past 4 weeks before inclusion
  • prior participation in this clinical trial

Sites / Locations

  • Department of Orthopedic Surgery

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Etoricoxib

Diclofenac

Arm Description

Outcomes

Primary Outcome Measures

Perioperative blood loss after implantation of a hip joint endoprosthesis
The primary objective of the study is the designation of the perioperative blood loss after implantation of a hip joint endoprosthesis under the influence of Etoricoxib or of Diclofenac. The expectations hypothesis is that under Etoricoxib patients will loose a smaller quantity of blood than under Diclofenac.

Secondary Outcome Measures

Heterotopic ossification
The secondary objectives are to investigate whether after hip joint endoprosthesis Etoricoxib can prevent heterotopic ossification in equal measure as Diclofenac
Postoperative pain
It will be investigated if Diclofenac and Etoricoxib effectively reduce postoperative pain after hip joint endoprosthesis at rest and during movement.
Reduction of rescue medication
It will be investigated whether Etioricoxib can reduce the use of rescue-medication as compared to Diclofenac
Gastroinstestinal tolerance
It will be investigated if the gastrointestinal tolerance of Etoricoxib is superior to the one of Diclofenac

Full Information

First Posted
October 27, 2010
Last Updated
September 12, 2014
Sponsor
University of Regensburg
Collaborators
Merck Sharp & Dohme LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT01229774
Brief Title
Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty
Official Title
Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty, a Prospective, Double Blind, Phase III Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2010
Overall Recruitment Status
Completed
Study Start Date
February 2011 (undefined)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
August 2014 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of Regensburg
Collaborators
Merck Sharp & Dohme LLC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary aim of this study is to test if etoricoxib decreases the perioperative blood loss compared to diclofenac. Secondary questions to be explored are: Does etoricoxib prevent Heterotopic ossification after Total Hip Arthroplasty as well as diclofenac ? Do diclofenac and etoricoxib both reduce pain at rest and on movements? Does etoricoxib compared to diclofenac reduce the amount of rescue medication (Oxycodon)? Does etoricoxib improve gastrointestinal tolerability compared to diclofenac?
Detailed Description
Total Hip Arthroplasty (THA) is a common surgical procedure in orthopaedic surgery which can be associated with perioperative blood loss and severe postoperative pain. Adequate pain management is very important to achieve early mobilisation in order to avoid immobility-induced complications. Non steroidal antirheumatic agents (NSAIDs) as selective Cox-2 inhibitors are commonly used in the management of postoperative pain. There exist non-selective and selective Cox-inihibitors. Non-selective NSAIDs block the systhesis of prostagandins by the two iso-enzymes of the cyclooxygenase, Cox-1 and Cox-2. For this reason the bleeding risk after operations (e.g.tonsillectomy) is increased. In this regard, the perioperative use of Cox-2 selective NSAIDs is advantageous for pain management after tonsillectomy. This could be shown for Rifecoxib, a selective Cox-2 inihibitor. For THAs with treatment of Etoricoxib, also a selective Cox-2 inhibitor, possible complications as the increased risk of haematoma, gastrointestinal bleeding and the need of blood transfusion could possibly be reduced. Selective Cox-2 inhibitors do not interfere with the coagulation system. Study results show that other selective Cox-2 inhibitors like meloxicam reduce perioperative blood loss. Thus, besides ensuring a good perioperative pain management, selective Cox-2 inhibitors may in addition cause less blood loss than non-selective NSAIDs.This possible reduction of blood loss during pain management with Etoricoxib (Arcoxia) will be investigated the described clinical trial. Heterotopic ossification (HO) is a complication occurring after THA which can lead to postoperative pain and reduced function. Non-selective NSAIDs are commonly used in the prophylaxis of heterotopic ossifications after THA. The exact mechanism of prevention of bone formation is unclear. Some results indicate that the development of HO follows a Cox-2 pathway. A further aim of this clinical trial is to investigate the efficacy of Etoricoxib in the prevention of heterotropic ossification.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coxarthrosis, Arthroplasties Hip Replacement, Perioperative Blood Loss

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Etoricoxib
Arm Type
Experimental
Arm Title
Diclofenac
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Etoricoxib
Intervention Description
Arcoxia 90 mg once a day in the evening day -1 and 0 and once a day in the morning days 1-7 plus on tablett of placebo every evening
Intervention Type
Drug
Intervention Name(s)
Diclofenac
Intervention Description
Voltaren Resinat 75mg once a day on day -1 and 0 in the evening; twice a day (in the morning and in the evening) days 1-7
Primary Outcome Measure Information:
Title
Perioperative blood loss after implantation of a hip joint endoprosthesis
Description
The primary objective of the study is the designation of the perioperative blood loss after implantation of a hip joint endoprosthesis under the influence of Etoricoxib or of Diclofenac. The expectations hypothesis is that under Etoricoxib patients will loose a smaller quantity of blood than under Diclofenac.
Time Frame
Three days
Secondary Outcome Measure Information:
Title
Heterotopic ossification
Description
The secondary objectives are to investigate whether after hip joint endoprosthesis Etoricoxib can prevent heterotopic ossification in equal measure as Diclofenac
Time Frame
six months
Title
Postoperative pain
Description
It will be investigated if Diclofenac and Etoricoxib effectively reduce postoperative pain after hip joint endoprosthesis at rest and during movement.
Time Frame
nine days
Title
Reduction of rescue medication
Description
It will be investigated whether Etioricoxib can reduce the use of rescue-medication as compared to Diclofenac
Time Frame
nine days
Title
Gastroinstestinal tolerance
Description
It will be investigated if the gastrointestinal tolerance of Etoricoxib is superior to the one of Diclofenac
Time Frame
nine days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Indication for THA because of primary and secondary osteoarthritis of the hip. male or female patients of the age of 55 - 85 years informed consent afer having been informed in detail about the clinical trial by the investigator negative pregnancy test (<= 2 days before inclusion) for women with child bearing potential (pre menopausal, <2 years menopausal, not surgically sterile), use of high security contraception methods as oral contraception agents or preservatives. The use of high security conception methods is also to obligatory for male patients Exclusion Criteria: Known hypersensitivity to one of the two investigational medical products or substaces of similar chemical structure or to any of the excipients Patients who have experienced bronchospasm, asthma, acute rhinitis, urticaria, or allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors unexplained dysfunction of haematopoiesis treatment with NSAIDs or coxiben in the past 5 days before start of study Active peptic ulceration or active gastro-intestinal (GI) bleeding Pregnancy and lactation Congestive heart failure (NYHA II-IV) Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease clinically relevant disease of the cardiovascular system, severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10), severe renal dysfunction (estimated renal creatinine clearance <30 ml/min, clinical relevant disease of the nervous system, the endocrinium or another severe systematic disease Systemic lupus erythematodes or mixed connective tissue disease Inflammatory bowel disease alcohol or drug abuse during the last past 3 months Patients with hypertension BP persistently > 140/90mmHG) and has not been adequately controlled life expectancy <6 months state of mind which does not enable the patient to understand the nature of the study, its importance and possible consequences evidence that the respective person will not cooperate with the study protocoll participation of the patient in another clinical trial during the past 4 weeks before inclusion prior participation in this clinical trial
Facility Information:
Facility Name
Department of Orthopedic Surgery
City
Bad Abbach
State/Province
Bavaria
ZIP/Postal Code
93077
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty

We'll reach out to this number within 24 hrs